Isabelle Freiling, PhD, Nicole M. Krause, MA, and Dietram A. Scheufele, PhD
Misinformation is an urgent new problem, so health professions communities need solutions as much as they need to be wary of ethical pitfalls of rushed interventions.
AMA J Ethics. 2023;25(3):E228-237. doi:
10.1001/amajethics.2023.228.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022;24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
Most physicians schedule out months in advance, requiring their patients to cope with their condition until their appointment and risk their suffering becoming discredited.
AMA J Ethics. 2022;24(12):E1181-1182. doi:
10.1001/amajethics.2022.1181.
Dr Jing Li joins Ethics Talk to discuss her article, coauthored with Dr Robert Tyler Braun, Sophia Kakarala, and Dr Holly G. Prigerson: “How Should Cost-Informed Goals of Care Decisions Be Facilitated at Life’s End?”